SECUKINUMAB (SECU) demonstrates sustained effectiveness and high drug survival rates in patients with moderate-to-severe ...
psoriatic arthritis and inflammatory bowel disease 14. However, all first-generation JAK inhibitors designed to target the enzyme family’s kinase domain exhibited some degree of cross-reactivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback